MetaCap

Azitra (AZTR) vs XTL Biopharmaceuticals (XTLB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

XTL Biopharmaceuticals is the larger company by market cap ($3.4 million vs $3.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AZTR+291.52%XTLB-30.81%
+1114%+507%-101%
Oct 7, 20261 yearNov 20, 2026
AZTR+297.84%XTLB-30.81%
+519%+224%-72%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AZTR versus XTLB key metrics
MetricAZTRXTLB
Share price$0.5168$1.37
Market cap$3.13M$3.37M
1-day change-2.75%-5.84%
EPS (TTM)$-12.40$-0.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$451.00K
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-10.96M$-1.03M
Gross margin—0.67%
Operating margin—-481.60%
Net margin—-227.72%
52-week high$3.91$5.64
52-week low$0.5086$1.37
Distance from 52-week high-86.78%-75.71%
Analyst consensusbuy—
Avg. price target upside+29.64%—
Average volume2.65M6.58K
Shares outstanding6.06M2.46M
Employees134
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Azitra

AZTR stock →

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About XTL Biopharmaceuticals

XTLB stock →

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

AZTR vs XTLB FAQ

Which is bigger, Azitra or XTL Biopharmaceuticals?

XTL Biopharmaceuticals (XTLB) is larger, with a market capitalization of $3.37M compared with $3.13M for Azitra (AZTR).

Are Azitra and XTL Biopharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons